FABP4 and Sepsis: Future work can test whether GPT-4 can improve the marginal performance of widely available clinical biomarkers such as C-reactive protein, assess the generalizability of FABP4/GPT-4 classifier performance in larger independent cohorts of ICU patients, and evaluate these methods for the diagnosis of other critical illness syndromes such as sepsis.